Managing bone health with zoledronic acid: a review of randomized clinical study results

References

• Hill PA. Bone remodelling. Br J Orthod 1998;25:101–7
   PubMedGoogle Scholar
• Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007;13:791–801
   PubMed Web of Science ®Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–57
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention and management of osteoporosis (WHO Technical Report Series 921). http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf , last accessed May 21, 2010
   Google Scholar
• Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420–32
   PubMed Web of Science ®Google Scholar
• Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19:1407–16
   PubMed Web of Science ®Google Scholar
• Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ, III, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172–8
   PubMed Web of Science ®Google Scholar
• Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733–8
   PubMed Web of Science ®Google Scholar
• Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010;28:967–75
   PubMed Web of Science ®Google Scholar
• Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008;14:6336–42
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77–85
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840–9
   PubMed Web of Science ®Google Scholar
• Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051–7
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655–64
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13:503–14
   PubMed Web of Science ®Google Scholar
• Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains suppression of osteolysis in patients with malignant bone disease. Presented at the 2008 IBMS Davos Workshops: Bone Biology & Therapeutics. Switzerland, Davos, 2008, Abstr 199.
   Google Scholar
• Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59–69
   PubMed Web of Science ®Google Scholar
• Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925–35
   PubMed Web of Science ®Google Scholar
• Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228–36
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193–201
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook RJ, Coleman RE, et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007;7:346–53
   PubMedGoogle Scholar
• US National Institutes of Health. Comparison of two schedules of zoledronic acid in treating patients with breast cancer that has spread to the bone. http://clinicaltrials.gov/ct2/show/NCT00458796 , last accessed May 21, 2010
   Google Scholar
• Bonjour JP, Theintz G, Law F, Slosman D, Rizzoli R. Peak bone mass. Osteoporos Int 1994;4(Suppl 1):S7–13
   PubMed Web of Science ®Google Scholar
• Christiansen C. Postmenopausal bone loss and the risk of osteoporosis. Osteoporos Int 1994;4(Suppl 1):S47–51
   Google Scholar
• Lindsay R, Christiansen C, Einhorn TA. Consensus development statement: who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7:1–6
   Web of Science ®Google Scholar
• Purohit A, Reed MJ. Regulation of estrogen synthesis in postmenopausal women. Steroids 2002;67:979–83
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. www.nof.org , last accessed May 21, 2010
   Google Scholar
• Siris ES, Chen Y-T, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108–12
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581–9
   PubMed Web of Science ®Google Scholar
• Kanis JA. FRAX® WHO fracture risk assessment tool. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. http://www.shef.ac.uk/FRAX/index.htm , last accessed May 21, 2010
   Google Scholar
• Hadji P, Ziller M, Maskow C, Albert U, Kalder M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry, and bone turnover in premenopausal women with breast cancer. Eur J Cancer 2009;45:3205–12
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. V.1.2009. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf , last accessed May 21, 2010
   Google Scholar
• Kataja V, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):10–14
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319–29
   PubMed Web of Science ®Google Scholar
• Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511–15
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089–93
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286–91
   PubMed Web of Science ®Google Scholar
• Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119–27
   PubMed Web of Science ®Google Scholar
• Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629–35
   PubMed Web of Science ®Google Scholar
• Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009;20:1203–9
   PubMed Web of Science ®Google Scholar
• Hadji P, Ziller M, Kieback DG, et al. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 2009;18:159–64
   PubMed Web of Science ®Google Scholar
• Hadji P, Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol 2007;34(Suppl 4):S4–10
   Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–2
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–57
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–71
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584–93
   PubMed Web of Science ®Google Scholar
• Ulrich U, Rhiem K, Schmolling J, et al. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 2001;264:186–90
   PubMed Web of Science ®Google Scholar
• Kavanagh KL, Dunford JE, Bunkoczi G, Russell RGG, Oppermann U. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem 2006;281:22004–12
   PubMed Web of Science ®Google Scholar
• Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006;103:7829–34
   PubMed Web of Science ®Google Scholar
• Rondeau JM, Bitsch F, Bourgier E, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006;1:267–73
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP, et al. Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235–42
   PubMed Web of Science ®Google Scholar
• Bianchi G, Sambrook P. Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures. Curr Med Res Opin 2008;24:2669–77
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Höer A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Pref Adhere 2009;3:25–30
   PubMed Web of Science ®Google Scholar
• Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007;6:305–13
   PubMed Web of Science ®Google Scholar
• Zometa (Summary of Product Characteristics) http://www.e ma.europa.eu/humandocs/PDFs/EPAR/zometa/emea-combined-h336en.pdf , last accessed May 21, 2010
   Google Scholar
• Bondronat (Summary of Product Characteristics). http://www.e ma.europa.eu/humandocs/PDFs/EPAR/Bondronat/H-101-PI-en. pdf , last accessed May 21, 2010
   Google Scholar
• BC Cancer Agency. Clodronate (Cancer Drug Manual). Revised January 2008. http://www.bccancer.bc.ca/NR/rdonlyres/5C389713-2051-42B2-8D93-9DB7C88625A8/28814/ClodronateMonograph_16Apr08_RW.pdf, last accessed May 21, 2010
   Google Scholar
• Aclasta (Summary of Product Characteristics). http://www.ema.europa.eu/humandocs/PDFs/EPAR/aclasta/emea-combined-h595en.pdf , last accessed May 21, 2010
   Google Scholar
• Bonviva (Summary of Product Characteristics). http://www.ema.europa.eu/humandocs/PDFs/EPAR/Bonviva/emea-combined-h501en.pdf, last accessed May 21, 2010
   Google Scholar
• Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956–62
   PubMed Web of Science ®Google Scholar
• Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005;139:101–11
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399–405
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735–44
   PubMed Web of Science ®Google Scholar
• Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326–31
   PubMed Web of Science ®Google Scholar
• Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007;13:223–9
   PubMedGoogle Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–91
   PubMed Web of Science ®Google Scholar
• Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 2009;116:433–9
   PubMed Web of Science ®Google Scholar
• Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at the ECCO 15–34th ESMO Multidisciplinary Congress, Berlin, Germany, September 2009. Eur J Cancer Suppl 2009;7:12, Abstr 20LBA.
   Web of Science ®Google Scholar
• Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Presented at the ECCO 15–34th ESMO Multidisciplinary Congress, Berlin, Germany, September 2009. Eur J Cancer Suppl 2009;7: Abstr 2LBA
   Google Scholar
• Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (Meeting Abstracts) 2010;28: LBA4507
   Web of Science ®Google Scholar
• Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826–36
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27:221–6
   PubMed Web of Science ®Google Scholar
• Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients – May 2006. Crit Rev Oncol Hematol 2007;62:148–52
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137–45
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117–20
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22
   PubMed Web of Science ®Google Scholar
• Bartl R, Gotte S, Hadji P, Hammerschmidt T. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Dtsch Med Wochenschr 2006;131:1257–62
   PubMed Web of Science ®Google Scholar
• Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303–10
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799–809
   PubMed Web of Science ®Google Scholar
• Reclast (prescribing information). http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf . Accessed September 9, 2010
   Google Scholar
• Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009;94:538–44
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010;28:3582–90
   PubMed Web of Science ®Google Scholar
• Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102:799–802
   PubMed Web of Science ®Google Scholar
• Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010;28:3577–81
   PubMed Web of Science ®Google Scholar
• Boniva (Prescribing Information). http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021858s001lbl.pdf , last accessed May 21, 2010
   Google Scholar
• Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895–6
   PubMed Web of Science ®Google Scholar
• Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826–31
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003;348:1187–8
   PubMed Web of Science ®Google Scholar
• Sharma NS, Ooi J-L, Masselos K, Hooper MJ, Francis IC. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 2008;359:1410–1
   PubMed Web of Science ®Google Scholar
• Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346–50
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761–71
   PubMed Web of Science ®Google Scholar
• Eidtmann H, De Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21:2188–94
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679–91
   PubMed Web of Science ®Google Scholar
• Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up, Presented at: American Society of Clinical Oncology 2009 Breast Cancer Symposium; October 8–10, 2009, San Francisco, CA: Abstr 213
   Google Scholar
• Frassoldati A, Brufsky A, Bundred N, et al. Effect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: a 24-month integrated follow-up of the Z-FAST/ZO-FAST trials. Presented at the Primary Therapy of Early Breast Cancer 11th International Conference, St. Gallen, Switzerland, March 2009, Abstr 132
   Google Scholar
• Brown JE, Ellis SP, Lester JE, et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007;13:5406–10
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010;102:1010–17
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Halabi S, Gibson G, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. J Clin Oncol 2008;26(Suppl):9s, Abstr 512
   Google Scholar
• Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306–11
   PubMed Web of Science ®Google Scholar
• Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453–75
   PubMed Web of Science ®Google Scholar
• Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421–8
   PubMed Web of Science ®Google Scholar
• Greenberg S, Park JW, Melisko ME, et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results. J Clin Oncol 2010;28(Suppl):114s, Abstr 1002
   PubMedGoogle Scholar
• Rack B, Jückstock J, Genss E, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010;30:1807–13
   PubMed Web of Science ®Google Scholar
• Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2008. Cancer Res 2009;69(Suppl):170s, Abstr 2048
   Google Scholar
• Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099–105
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314–21
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–87
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2008:1–44
   Google Scholar